GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Alumis Inc (NAS:ALMS) » Definitions » Shares Outstanding (Basic Average)

ALMS (Alumis) Shares Outstanding (Basic Average) : 54.41 Mil (As of Dec. 2024)


View and export this data going back to 2024. Start your Free Trial

What is Alumis Shares Outstanding (Basic Average)?

Shares outstanding are shares that have been authorized, issued, and purchased by investors and are held by them. Alumis's average basic shares outstanding for the quarter that ended in Dec. 2024 was 54.41 Mil.


Alumis Shares Outstanding (Basic Average) Historical Data

The historical data trend for Alumis's Shares Outstanding (Basic Average) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Alumis Shares Outstanding (Basic Average) Chart

Alumis Annual Data
Trend Dec22 Dec23 Dec24
Shares Outstanding (Basic Average)
38.41 51.85 28.34

Alumis Quarterly Data
Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24
Shares Outstanding (Basic Average) Get a 7-Day Free Trial Premium Member Only 51.85 38.41 2.45 53.75 54.41

Alumis Shares Outstanding (Basic Average) Calculation

Shares outstanding are shares that have been authorized, issued, and purchased by investors and are held by them. They have voting rights and represent ownership in the corporation by the person that holds the shares. They should be distinguished from treasury shares, which are shares held by the corporation itself, having no exercisable rights.

Shares outstanding can be calculated as either basic or fully diluted. The fully diluted shares outstanding count includes diluting securities, such as options, warrants or convertibles.

Please note: GuruFocus named Shares Outstanding (EOP) is the shares for that exact time point. It is usually used to calculate balance sheet related items, such as Book Value per Share, etc. While Shares Outstanding (Diluted Average) and Shares Outstanding (Basic Average) are the weighted average shares over a period of time (a year, a quarter, or so). They are usually used to calculate income statement or cashflow statement related items, such as Earnings per Share (Diluted), etc.


Alumis  (NAS:ALMS) Shares Outstanding (Basic Average) Explanation

A company may buy back shares or issue shares in any fiscal period. If a company buys back shares, we should observe that the total number of shares decline. If the company issues new shares, the number of shares outstanding increases.


Be Aware

Usually the presence of treasury shares and a history of buyback are good indicators that company has competitive advantage. But studies have shown that companies usually buy back at wrong time. Buying back shares below its intrinsic value increases value for remaining shareholders. Buying back overvalued shares destroys value for existing shareholders.


Alumis Shares Outstanding (Basic Average) Related Terms

Thank you for viewing the detailed overview of Alumis's Shares Outstanding (Basic Average) provided by GuruFocus.com. Please click on the following links to see related term pages.


Alumis Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Alumis Inc (NAS:ALMS) » Definitions » Shares Outstanding (Basic Average)
Traded in Other Exchanges
N/A
Address
280 East Grand Avenue, South San Francisco, CA, USA, 94080
Alumis Inc is a clinical-stage biopharmaceutical company focused on identifying, acquiring, and accelerating the development and commercialization of transformative medicines for autoimmune disorders. The Company leverages its proprietary precision data analytics platform, biological insights, and a team of experts with deep experience in precision medicine drug discovery, development, and immunology, to create medicines that significantly improve the lives of patients by replacing broad immunosuppression with targeted therapies.

Alumis Headlines